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Abstract
Background:  We have previously demonstrated that therapy with orally administered L-
glutamine improves nicotinamide adenosine dinucleotide (NAD) redox potential of sickle red
blood cells (RBC). On further analysis of L-glutamine therapy for sickle cell anemia patients, the
effect of L-glutamine on adhesion of sickle RBC to human umbilical vein endothelial cells (HUVEC)
was examined.
Methods: The first part of the experiment was conducted with the blood samples of the 5 adult
sickle cell anemia patients who had been on L-glutamine therapy for at least 4 weeks on a dosage
of 30 grams per day compared to those of patient control group. In the second part of the
experiment 6 patients with sickle cell anemia were studied longitudinally. Five of these patients
were treated with oral L-glutamine 30 grams daily and one was observed without treatment as the
control. t-test and paired t-test were used for determination of statistical significance in cross-
sectional and longitudinal studies respectively.
Results: In the first study, the mean adhesion to endothelial cells with the autologous plasma
incubated cells were 0.97 ± 0.45 for the treated group and 1.91 ± 0.53 for the nontreated group
(p < 0.02). Similarly with lipopolysaccharide (LPS) incubated cells the mean adhesion to endothelial
cells were 1.39 ± 0.33 for the treated group and 2.80 ± 0.47 for the untreated group (p < 0.001).
With the longitudinal experiment, mean decrease in the adhesion to endothelial cells was 1.13 ±
0.21 (p < 0.001) for the 5 treated patients whereas the control patient had slight increase in the
adhesion to endothelial cells.
Conclusion:  In these studies, oral L-glutamine administration consistently resulted in
improvement of sickle RBC adhesion to HUVEC. These data suggest positive physiological effects
of L-glutamine in sickle cell disease.
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Background
Sickle cell disease is a devastating hereditary disorder with
excruciating morbidities often resulting in the premature
demise of the patients. This disease affects primarily those
of African descent, although other ethnic groups such as
the Hispanic population on American continents are also
affected with relatively high incidence [1-3].
Incapacitating complications of sickle cell disease are usu-
ally due to severe anemia and frequent vasoocclusive
processes which damage tissues [1-6]. The cause of these
events is attributed largely to increased adherence of sickle
red blood cells to vascular endothelium[4,7,8]. With alter-
ation in adherence to endothelial cells, sickle RBC will
have a longer transit time through capillaries which leads
to vasoocclusion with accumulation of less deformable
deoxygenated sickle RBC [7-9]. Thus, amelioration of
pathologic RBC adherence is considered to be an impor-
tant target in therapy of sickle cell disease.
In the current article, the effect of L-glutamine therapy on
sickle RBC adherence to HUVEC cells is presented. L-
glutamine is a precursor to NAD[10,11]. Previous studies
have shown that oral L-glutamine therapy improves NAD
redox potential of sickle RBC[10]. Also, among those
patients treated with L-glutamine, there were subjective
reports of improvement in clinical paramenters such as
chronic pain and energy level[10].
The study presented here was conducted in an attempt to
better understand mechanism by which L-glutamine may
potentially exert a beneficial effect on sickle RBC. In the
cohort that we have studied, oral L-glutamine therapy
consistently led to reduced adhesion of sickle RBC to
HUVEC in static assays with both cross-sectional and lon-
gitudinal studies.
Methods
Cross-sectional study
Reagents
LPS (lipopolysaccharide) preparation (Escherichia coli
0111:B4), Hanks' buffered saline solution, bovine serum
albumin (BSA), HEPES buffer and all other chemicals
were from Sigma Chemicals Co (St Louis, MO). Six-wells
tissue culture plates and Falcon Primaria tissue culture
flasks were from Fisher scientific (Pittsburgh, PA).
Sodium-51Chromate (51Cr) and Aquasol scintillation
fluid were obtained from NEN (Dupont NEN, Wilming-
ton, DE).
Cell cultures
HUVEC were harvested from umbilical cord veins by col-
lagenase digestion, as previously described[12]. Endothe-
lial cells were identified by their cobblestone
morphology, immunofluorescence staining with factor
VIII-related antigen and uptake of diacetylated low-den-
sity lipoprotein (Biomedical Technologies, Stoughton,
MA). Cells were passaged by trypsinization with 1%
trypsin-EDTA (GIBCO BRL, Grand Island, NY) every 4–5
days. HUVEC were used from passages 2 to 6.
Patients, control and blood samples
Blood samples were drawn from homozygous sickle cell
patients living in the Los Angeles area or from volunteer
control subjects after obtaining informed consent as
approved by the Harbor-UCLA Committee on Human
Research. All subjects were in steady state condition with-
out acute conditions including painful crisis. Nine adult
sickle cell anemia patients 18 years and older participated.
The treatment group consisted of 5 patients (mean age of
38.8 ± 7.8 with range of 30 to 47) who had been on L-
glutamine therapy continuously for 8 weeks or longer at
the dosage of 30 grams orally per day. The sickle cell con-
trol group consisted of 4 patients (mean age of 29.3 ± 9.0
with range of 20 to 37) who had not been on L-glutamine
or any other anti-sickling therapy for at least a year. One
of the patients in the non-treatment group participated at
two separate time points as sickle cell control. Normal
control samples were drawn from healthy volunteers.
51Cr labeling of RBC
Five to 7 ml of heparinized blood from normal donors
and sickle cell subjects were centrifuged at 450 × g for 20
min and plasma was saved in a refrigerator and the buffy
coat (leukocytes and platelets) was discarded. The pellet
was washed three times in Hanks' buffered saline solution
with centrifugation at 450 × g for 5 minutes and then RBC
were suspended to 20% hematocrit in 5 ml HBSS (Hanks'
buffered saline solution). RBC in HBSS were incubated
with 10 µCi/ml 51Cr for 1 hr at 37°C with 5% CO2.
Static assay for the adherence of RBC to cultured HUVEC
51Cr-sodium chromate-labeled RBC were washed three
times with 10 vol of HBSS and used at a hematocrit of 2%
in HBSS. HUVEC grown to confluence in 6-well plates
were washed twice with HBSS (3 ml) followed by the
addition of 51Cr-labeled RBC (hct 2%) and HBSS to a final
volume of 1 ml. Five percent autologous platelet-free
plasma (3 wells) or 100 ng/ml of LPS (3 wells) was added
and the contents were incubated for 45 minutes at 37°C
with 5% CO2. Nonadherent RBC were removed by aspira-
tion and monolayers were washed three times with 1 mL
of HBSS containing 0.5% BSA.200 ul lysis buffer was
added to each well and lysis solution was transferred to
scintillation vial. 5 µl RBC was added to 200 µl lysis buffer
and the solution was used as the baseline value. Two µl of
scintillation solution were added to each vial and the radi-
oactivity in the cell monolayer-containing adherent RBC
was determined and the percentage of RBC adherent was
calculated[8,13].BMC Blood Disorders 2005, 5:4 http://www.biomedcentral.com/1471-2326/5/4
Page 3 of 7
(page number not for citation purposes)
Statistical analysis
The ratio of percent adhesion of patient samples to that of
normal control was obtained for each sample. The statis-
tical significance of difference of the ratio between the
treatment groups was determined using t-test.
Longitudinal study
Reagents
Bovine serum albumin, Hanks' buffered saline solution,
calcium/magnesium-free phosphate-buffered saline, elec-
tron microscopic grade glutaraldehyde, and HEPES buffer
were from Sigma Chemicals Co (St Louis, MO). Human
umbilical vein endothelial cells, subculture reagent pack-
age (Trypsin EDTA, HEPES Buffered Saline Solution,
Trypsin Neutralizing Solution) and endothelial cell
growth medium (EGM) including all supplements and
growth factors were from Clonetics Corp (San Diego, CA).
Two-chambered culture slides, Falcon Primaria tissue cul-
ture flasks were from Fisher Scientific (Pittsburgh, PA).
Cell culture
Cells were grown at 37°C in 5% CO2/95% air in EGM at
85% confluence; the cells were subcultured to 2 cham-
bered slides. The second to the fourth passages were used
for adherence assays no later than 24 hours after HUVEC
had reached confluence.
Patients, control and blood samples
Blood samples were drawn from homozygous sickle cell
patients of the Harbor-UCLA Medical Center or from vol-
unteer control subjects after obtaining informed consent
as approved by the Harbor-UCLA Committee on Human
Research. All subjects were in steady state condition, none
had received blood transfusions within 4 months, and
none had history of treatment with hydroxyurea. Six adult
sickle cell anemia patients 18 years of age and older par-
ticipated. Five patients (mean age 40.0 ± 16.4 with range
of 19 to 57) were treated for 4 to 8 weeks with oral L-
glutamine at dosage of 30 grams a day. One patient (49
years old) who served as sickle cell control had no treat-
ment. The whole blood samples were drawn at baseline
which was within 4 weeks of initiation of therapy and
then after 4 to 8 weeks of therapy with L-glutamine for the
5 patients. The blood samples of untreated sickle cell con-
trol patient were drawn along with the treatment patients
at baseline and then 8 weeks later. For each assay, normal
control blood was also drawn from normal volunteers.
Gravity adherence assays
This method of assaying static adherence of RBC to
HUVEC monolayers was adapted from a published
method[14]. Heparinized blood from normal donors and
sickle cell subjects was centrifuged at 5000 × g for 5 min-
utes and plasma was saved in the refrigerator and buffy
coat (leukocyte and platelets) was discarded. RBC were
washed three times in Hanks' buffered saline solution,
centrifuged at 1000 × g for 5 minutes. RBC were then cen-
trifuged at 5000 × g and suspended to 3.5% hematocrit in
HAH buffer (Hanks' buffered saline solution, 1% BSA, 50
mmol/L HEPES pH 7.4) containing 17% autologous
platelet-free plasma from the heparinized blood sample.
Confluent HUVEC monolayers were washed with HAH
buffer to remove traces of plasma. After washing with
HAH buffer, each well was filled with 0.8 ml HAH and
one well was treated with LPS (200 ng/ml) and incubated
at 37 C, 5%CO2, 95% humidity for 1 hr. After treating
cells with LPS for 1 hr, the monolayers were covered with
sickle cell (SS) RBC suspensions and incubated at 37°C
for 25 minutes. The wells were then filled completely with
HAH, sealed with packing tape, and inverted at 37°C for
20 minutes. While still inverted, the well walls and gaskets
of the slide chambers were removed. The slides were
rinsed twice with HAH buffer to remove nonadherent
RBC, fixed in 3% glutaraldehyde, stained, and mounted.
RBC adherence was monitored visually by microscopy at
100× magnification and quantified by counting RBC
adherent to HUVEC monolayers in 16 fields marked by a
grid (same random fields for each sample). The mean
adherence and standard error of mean (SEM) for each
sample were calculated and results were used to determine
the reported means from at least four experiments, only
when the SEM of each sample was less than 20% of the
means. Results were analyzed by the Student's t-test, with
which p < 0.05 was considered significant.
Statistical analysis
The ratio of mean endothelial adhesion RBC of patient
samples to that of normal control was obtained for each
sample. The statistical significance of difference of the
ratio between the baseline and after treatment was deter-
mined using paired t-test.
Results
Cross-sectional study
The mean ratios with assays using autologous plasma and
LPS incubated cells were 0.97 ± 0.45 and 1.39 ± 0.33,
respectively for the L-glutamine treated group (N = 5). For
the untreated group the mean ratios were 1.91 ± 0.53 and
2.80 ± 0.47 for autologous plasma and LPS incubated cells
respectively (N = 4 with one of the patients studied twice
at two time points) The decreased adhesion to endothelial
cells by the L-glutamine treated group were statistically
significant in both assays with autologous plasma incu-
bated cells (p < 0.02) and LPS incubated cells (p < 0.001)
(Figures 1 and 2). The endothelial adhesion of RBC from
non-treated sickle cell patients were as expected and sev-
eral fold higher than that of normal control. On the other
hand, the results of the treatment group were consistently
similar to that of the normal control, thus resulting in
ratio of close to 1 for both assays using LPS or autologousBMC Blood Disorders 2005, 5:4 http://www.biomedcentral.com/1471-2326/5/4
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plasma only. Because of the relatively small size of
cohorts, there was a trend for age difference in the ages of
the two groups, mean age of 38.8 ± 7.8 with range of 30
to 47 for the treatment group and 29.3 ± 9.0 with range of
20 to 37 for the non-treatment group. However, there was
no statistical significance with p > 0.1.
Longitudinal study
In contrast to the cross-sectional study, for this portion of
experiment, each patient became his/her own reference
and provided baseline value. The results were consistent
with the data of cross-sectional study noted above. Com-
pared to the baseline value, the endothelial adhesion of
sickle RBC decreased in each patient (N = 5) within 4 to 8
weeks of oral L-glutamine therapy. The mean decrease was
1.13 ± 0.21 with p < 0.001. For the patient who partici-
pated as sickle cell control, the sickle RBC adhesion to
endothelial cells increased slightly compared to the base-
line (Figure 3).
Discussion
The vaso-occlusive process is mediated primarily by con-
gestion and closure of the microvasculature with rigid
sickle RBC[4,8,15]. It is well described that the oxygenated
sickle RBC is relatively deformable but it starts to become
less so upon unloading of oxygen molecules to tissue[16].
The duration of time required for sickle RBC to become
less deformable is thought to be more than the usual cap-
illary transit time for RBC[7,9]. Therefore, had it not been
for the prolonged capillary transit time, the sickle RBC
would have already exited the microvascular system
Ratios of HUVEC adhesion rates of sickle RBC to those of  normal RBC for the treatment group (0.97 ± 0.45) and non- treatment group (1.91 ± 0.53) when the cells were incubated  with autologous plasma alone Figure 1
Ratios of HUVEC adhesion rates of sickle RBC to those of 
normal RBC for the treatment group (0.97 ± 0.45) and non-
treatment group (1.91 ± 0.53) when the cells were incubated 
with autologous plasma alone. (p < 0.02)
Ratios of HUVEC adhesion rates of sickle RBC to those of  normal RBC for the treatment group (1.39 ± 0.33) and non- treatment group (2.80 ± 0.47) when the cells were incubated  with autologous plasma and LPS Figure 2
Ratios of HUVEC adhesion rates of sickle RBC to those of 
normal RBC for the treatment group (1.39 ± 0.33) and non-
treatment group (2.80 ± 0.47) when the cells were incubated 
with autologous plasma and LPS. (p < 0.001)
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Ratios of HUVEC adhesion rates of sickle RBC to those of  normal RBC before and after treatment for the five sickle cell  anemia patients with one sickle cell anemia control patient  who was not treated Figure 3
Ratios of HUVEC adhesion rates of sickle RBC to those of 
normal RBC before and after treatment for the five sickle cell 
anemia patients with one sickle cell anemia control patient 
who was not treated. Mean decrease of the adhesion ratios 
was 1.13 ± 0.21 with p < 0.001 for the five treated patients, 
whereas the control patient actually had slight increase in the 
adhesion ratio over the same period.
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before it becomes less deformable and trapped in the
microvasculature. Thus, factors that affect the capillary
transit time become crucial in initiation and propagation
of vaso-occlusive event.
When Hebbel and colleagues first reported an increase in
endothelial adhesion of sickle RBC two decades ago, one
of the major factors involved in the pathophysiology of
vasoocclusion started to unfold[8]. Since then, several
endothelial adhesion molecules which are abnormally
expressed in both RBC and endothelial cells of sickle cell
disease patients have been described[7,14,17,18]. Also,
involvement of leukocytes, platelets and inflammation in
general with endothelial adhesion has been
described[4,19,20].
In the study presented in this article, endothelial adhesion
of sickle RBC was used as the primary end point to evalu-
ate the efficacy of L-glutamine therapy. Although clinical
outcome measurements, such as the incidence of sickle
cell crises or mortality rate cannot be replaced for
endothelial adhesion of sickle RBC, it may be a reasonable
surrogate in predicting clinical efficacy of an experimental
therapeutic modality.
A role for L-glutamine in sickle cell disease was conceived
when Zerez and colleagues looked closely into the redox
process in sickle RBC focusing on NAD which is a potent
antioxidant[21]. L-glutamine is a precursor for NAD. In
sickle RBC, NAD metabolism is altered favoring an
increase in the synthesis of NAD but with decreased NAD
redox potential[21] As NAD is a major antioxidant
molecule in RBC, the phenomenon of increased synthesis
for NAD with decreased NAD redox potential was inter-
preted as a compensatory mechanism of sickle RBC in the
presence of increased oxidant stress[21]. The presence of
increased oxidant stress and oxidant susceptibility of
sickle cell has been described independently by numerous
investigators[20,22-25]. Additional studies suggested that
supplementation with the precursor of NAD, L-glutamine,
may further enhance the NAD redox system[26].
With 30 grams of L-glutamine supplementation, there was
improvement in NAD redox potential in 7 out of 7
patients. In addition, there were consistent reports of
improved general clinical condition in such areas as
energy level and chronic pain levels [10]. Furthermore, a
short observation period of approximately 3 months sug-
gested a decrease in the incidence of vaso-occlusive pain-
ful crises among those patients.
On the basis of these results, we proceeded to study the
effect of L-glutamine therapy on endothelial adhesion of
sickle RBC. As noted in the data presented here, in both
cross-sectional and longitudinal studies, there is an
indication that L-glutamine therapy improves the
endothelial adhesion of sickle RBC.
In the cross-sectional study, patients who were already on
the L-glutamine therapy were compared to those who
have never been treated with L-glutamine. The adhesion
in the untreated group was elevated as expected, which
was consistent with previously published reports. On the
other hand, the adhesion for the treatment group was very
similar to those of normal control.
To confirm the cross-sectional data, the prospective study
was conducted on 5 sickle cell anemia patients who were
treated for 4 to 8 weeks. The results were consistent among
each patient studied. With the therapy, each patient had
significant improvement in endothelial adhesion while
there was no improvement in the control patient who was
not treated. The stimulants for endothelial cells were
taken from the methods used in the previous studies by
Kalra and collegues[13]. Their method is well established
for static assay and based on their data, we felt their meth-
ods were applicable in our project. Adhesion assay for the
cross-sectional study and longitudinal studies were con-
ducted at two separate institutions but using same agents
to stimulate the endothelial cells. The purpose of utilizing
two expert sites for two parts of study was to improve
objectivity by demonstrating that consistent data can be
obtained even when assays were conducted by unbiased
experts at multiple independent sites.
In the studies, we could not verify the increase in RBC sur-
vival duration as neither reticulocyte counts nor hemo-
globin levels were not changed significantly. However,
improvement in endothelial adhesion does not have to
automatically result in increase in RBC survival. As these
patients are asplenic, irreversibly sickled RBC are not rap-
idly removed and they will contribute to hemoglobin and
hematocrit levels. Also, it is possible that with larger study
with longer duration, there may be a change in these
parameters with statistical significance. In general mor-
phology of RBC appeared to have improved [see addi-
tional file 1 and 2].
Adhesion was assessed using a static endothelium-RBC
adhesion system rather than a dynamic assay under con-
ditions of flow over time. The decision to use the static
assay was based on previous reports including that of the
seminal article by Hebbel and colleagues[8,12,27]. In
addition, as noted by Setty and others, the static assay may
better simulate the interaction of sickle RBC and endothe-
lium where microvessel flow may be slow and intermit-
tent [27-29]. Obviously, there are also data suggesting that
the dynamic endothelium-RBC adhesion system may bet-
ter represent the in vivo activity. Such data favoring flow
based assay may be found in the studies by Libowsky andBMC Blood Disorders 2005, 5:4 http://www.biomedcentral.com/1471-2326/5/4
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colleagues, demonstrating with intravital microscopy that
sickle RBC that became adherent during stasis created by
a pressure cuff, dislodged when the cuff was removed and
the flow resumed[30,31]. It is doubtful that there is an in
vitro system that will perfectly represent the in vivo process.
Rather, it is likely that both static and dynamic assays have
roles in the investigation of sickle cell pathophysiology.
At present, the exact mechanism by which L-glutamine
effectively decreases the endothelial adhesion of sickle
RBC is not clear. However, there is evidence suggesting
that one of the ways L-glutamine may benefit sickle RBC
is by improvement of NAD redox potential[10]. This may
prevent oxidant damage to RBC which may result in stim-
ulation of inflammation and expression of adhesion mol-
ecules. In addition, L-glutamine may provide much
needed energy and building material to maintain the
integrity of sickle RBC. It has been reported that sickle cell
children require increased amino acid consumption, espe-
cially glutamine[32].
Conclusion
L-glutamine is an inexpensive compound widely con-
sumed as part of a normal diet or as a dietary supplement.
There is essentially no major adverse effect when used as
an oral agent both in a research setting and non-research
setting [33-36]. The data gathered so far including the
ones presented in this article suggest that there is a physi-
ological basis for the potential clinical benefit of L-
glutamine in management of sickle cell disease patients.
List of abbreviations
NAD = Nicotinamide Adenosine Dinucleotide
RBC = Red Blood Cells
HUVEC = Human Umbilical Vein Endothelial Cells
LPS = Lipopolysaccharide
BSA = Bovine Serum Albumin
HBSS = Hank's Buffered Saline Solution
HEPES = 4-(2-hydroxyethyl)-1 – piperazineethanesul-
fonic acid
EGM = Endothelial Cell Growth Medium
SEM = Standard Error of Mean
Competing interests
YN and KRT have proprietary interest in the product tested
in this study.
Non-financial competing interests
None
Authors' contributions
YN is the primary investigator and senior author. YN con-
ceived of the study, designed and coordinated the study.
YN also drafted the manuscript. NMM and YMS per-
formed the endothelial adhesion assays and coordinated
with SHE and VKK in the analysis and interpretation of
data. SHC, DAA, MAS and JM were involved in acquisition
of patient data as well ad the performance of various
assays. CSJ and KRT have been involved in the conception
of the study as well as in supervising composition of man-
uscript. All authors read and approved the manuscript.
Acknowledgements
This work was supported by NIH/NHLBI Grant: 1R29HL58640 and 
FDAOPD Grant: FD-R-002028. This work was also supported by Los 
Angeles Biomedical Research Institute at Harbor-UCLA Medical Center 
and NIH supported General Clinical Research Center at Harbor-UCLA 
Medical Center.
References
1. Hamdallah M, Bhatia AJ: Prevalence of sickle-cell trait in USA
adolescents of Central American origin.  Lancet 1995,
346:707-8.
2. Weissman AM: Preventive health care and screening of Latin
American immigrants in the United States.  J Am Board Fam
Pract 1994, 7:310-23.
3. Diaz-Barrios V: Newborn screening for sickle cell disease and
other hemoglobinopathies. New York's experience.  Pediatrics
1989, 83:872-5.
4. Frenette PS: Sickle cell vaso-occlusion: multistep and multicel-
lular paradigm.  Curr Opin Hematol 2002, 9:101-6.
5. Perronne V, Roberts-Harewood M, Bachir D, Roudot-Thoraval F,
Delord JM, Thuret I, Schaeffer A, Davies SC, Galacteros F, Godeau B:
Patterns of mortality in sickle cell disease in adults in France
and England.  Hematol J 2002, 3:56-60.
6. Wierenga KJ, Hambleton IR, Lewis NA: Survival estimates for
patients with homozygous sickle-cell disease in Jamaica: a
clinic-based population study.  Lancet 2001, 357:680-3.
7. Barabino GA, McIntire LV, Eskin SG, Sears DA, Udden M: Endothe-
lial cell interactions with sickle cell, sickle trait, mechanically
injured, and normal erythrocytes under controlled flow.
Blood 1987, 70:152-7.
8. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW:
Abnormal adherence of sickle erythrocytes to cultured vas-
cular endothelium: possible mechanism for microvascular
occlusion in sickle cell disease.  J Clin Invest 1980, 65:154-60.
9. Vargas FF, Blackshear GL: Vascular resistance and transit time
of sickle red blood cells.  Blood Cells 1982, 8:139-45.
10. Niihara Y, Zerez CR, Akiyama DS, Tanaka KR: Oral L-glutamine
therapy for sickle cell anemia: I. Subjective clinical improve-
ment and favorable change in red cell NAD redox potential.
Am J Hematol 1998, 58:117-21.
11. Zerez CR, Lachant NA, Lee SJ, Tanaka KR: Decreased erythrocyte
nicotinamide adenine dinucleotide redox potential and
abnormal pyridine nucleotide content in sickle cell disease.
Blood 1988, 71:512-5.
12. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL, Coates TD:
Mechanism of cigarette smoke condensate induced adhesion
of human monocytes to cultured endothelial cells.  J Cell Physiol
1994, 160:154-62.
13. Wali RK, Jaffe S, Kumar D, Kalra VK: Alterations in organization
of phospholipids in erythrocytes as factor in adherence to
endothelial cells in diabetes mellitus.  Diabetes 1988, 37:104-11.
14. Sugihara K, Sugihara T, Mohandas N, Hebbel RP: Thrombospondin
mediates adherence of CD36+ sickle reticulocytes to
endothelial cells.  Blood 1992, 80:2634-42.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Blood Disorders 2005, 5:4 http://www.biomedcentral.com/1471-2326/5/4
Page 7 of 7
(page number not for citation purposes)
15. Hebbel RP, Schwartz RS, Mohandas N: The adhesive sickle eryth-
rocyte: cause and consequence of abnormal interactions
with endothelium, monocytes/macrophages and model
membranes.  Clin Haematol 1985, 14:141-61.
16. Ohnishi ST, Horiuchi KY, Horiuchi K: The mechanism of in vitro
formation of irreversibly sickled cells and modes of action of
its inhibitors.  Biochim Biophys Acta 1986, 886:119-29.
17. Hebbel RP, Eaton JW, Steinberg MH, White JG: Erythrocyte/
endothelial interactions in the pathogenesis of sickle-cell dis-
ease: a "real logical" assessment.  Blood Cells 1982, 8:163-73.
18. Sultana C, Shen Y, Rattan V, Johnson C, Kalra VK: Interaction of
sickle erythrocytes with endothelial cells in the presence of
endothelial cell conditioned medium induces oxidant stress
leading to transendothelial migration of monocytes.  Blood
1998, 92:3924-35.
19. Inwald DP, Kirkham FJ, Peters MJ, Lane R, Wade A, Evans JP, Klein NJ:
Platelet and leucocyte activation in childhood sickle cell dis-
ease: association with nocturnal hypoxaemia.  Br J Haematol
2000, 111:474-81.
20. Rattan V, Sultana C, Shen Y, Kalra VK: Oxidant stress-induced
transendothelial migration of monocytes is linked to phos-
phorylation of PECAM-1.  Am J Physiol 1997, 273:E453-61.
21. Zerez CR, Lachant NA, Lent KM, Tanaka KR: Decreased pyrimi-
dine nucleoside monophosphate kinase activity in sickle
erythrocytes.  Blood 1992, 80:512-6.
22. Klings ES, Farber HW: Role of free radicals in the pathogenesis
of acute chest syndrome in sickle cell disease.  Respir Res 2001,
2:280-5.
23. Anastasi J: Hemoglobin S-mediated membrane oxidant injury:
protection from malaria and pathology in sickle cell disease.
Med Hypotheses 1984, 14:311-20.
24. Wetterstroem N, Brewer GJ, Warth JA, Mitchinson A, Near K: Rela-
tionship of glutathione levels and Heinz body formation to
irreversibly sickled cells in sickle cell anemia.  J Lab Clin Med
1984, 103:589-96.
25. Beretta L, Gerli GC, Ferraresi R, Agostoni A, Gualandri V, Orsini GB:
Antioxidant system in sickle red cells.  Acta Haematol 1983,
70:194-7.
26. Niihara Y, Zerez CR, Akiyama DS, Tanaka KR: Increased red cell
glutamine availability in sickle cell anemia: demonstration of
increased active transport, affinity, and increased glutamate
level in intact red cells.  J Lab Clin Med 1997, 130:83-90.
27. Setty BN, Kulkarni S, Stuart MJ: Role of erythrocyte phosphati-
dylserine in sickle red cell-endothelial adhesion.  Blood 2002,
99:1564-71.
28. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW,
Bonner RF: Periodic microcirculatory flow in patients with
sickle-cell disease.  N Engl J Med 1984, 311:1534-8.
29. Wun T, Paglieroni T, Field CL, Welborn J, Cheung A, Walker NJ, Tab-
lin F: Platelet-erythrocyte adhesion in sickle cell disease.  J
Investig Med 1999, 47:121-7.
30. Lipowsky HH, Sheikh NU, Katz DM: Intravital microscopy of cap-
illary hemodynamics in sickle cell disease.  J Clin Invest 1987,
80:117-27.
31. Lipowsky HH, Williams ME: Shear rate dependency of red cell
sequestration in skin capillaries in sickle cell disease and its
variation with vasoocclusive crisis.  Microcirculation 1997,
4:289-301.
32. Salman EK, Haymond MW, Bayne E, Sager BK, Wiisanen A, Pitel P,
Darmaun D: Protein and energy metabolism in prepubertal
children with sickle cell anemia.  Pediatr Res 1996, 40:34-40.
33. Garlick PJ: Assessment of the safety of glutamine and other
amino acids.  J Nutr 2001, 131:2556S-61S.
34. Ziegler TR, Bazargan N, Leader LM, Martindale RG: Glutamine and
the gastrointestinal tract.  Curr Opin Clin Nutr Metab Care 2000,
3:355-62.
35. Hasebe M, Suzuki H, Mori E, Furukawa J, Kobayashi K, Ueda Y:
Glutamate in enteral nutrition: can glutamate replace
glutamine in supplementation to enteral nutrition in burned
rats?  JPEN J Parenter Enteral Nutr 1999, 23:S78-82.
36. Ziegler TR, Benfell K, Smith RJ, Young LS, Brown E, Ferrari-Baliviera
E, Lowe DK, Wilmore DW: Safety and metabolic effects of L-
glutamine administration in humans.  JPEN J Parenter Enteral
Nutr 1990, 14:137S-146S.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2326/5/4/prepub